L L Worth, S S Jeha, E S Kleinerman
Index: Hematol. Oncol. Clin. North Am. 15(4) , 723-40, ix, (2001)
Full Text: HTML
Biologic response modifiers are becoming an important addition to surgery, chemotherapy, and radiotherapy in the management of cancer. As this field of research grows and expands, more biologic response modifiers will be incorporated into therapeutic regimens. By stimulating the immune system to eradicate minimal residual disease, these agents may improve the disease-free and long-term survival rates of patients with a variety of malignancies. The challenge is to incorporate biologic response modifiers into the treatment armamentarium in ways that will maximize their tumorigenicity.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
Mifamurtide
CAS:83461-56-7 |
C59H109N6O19P |
|
Muramyl tripeptide (mifamurtide) for the treatment of osteos...
2009-08-01 [Expert Rev. Anticancer Ther. 9(8) , 1035-49, (2009)] |
|
Imunomodulative effect of liposomized muramyltripeptide phos...
2008-09-01 [Parasitol. Res. 103(4) , 919-29, (2008)] |
|
In vitro and in vivo enhancement of canine pulmonary alveola...
1999-04-01 [Cancer Biother. Radiopharm. 14(2) , 121-8, (1999)] |
|
Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for ...
1998-10-01 [Cancer Biother. Radiopharm. 13(5) , 363-8, (1998)] |
|
Effect of MTP on TNF-alpha in perfused rat liver after bacte...
1998-05-01 [J. Surg. Res. 76(2) , 179-84, (1998)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
